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Abstract 
The presence of the endogenous Leishmania RNA virus 1 (LRV1) replicating stably within 
some parasite species has been associated with the development of more severe forms of 
leishmaniasis and relapses after drug treatment in humans. Here, we show that the disease 
exacerbatory role of LRV1 relies on Type I interferon (Type I IFNs) production by 
macrophages and signaling in vivo. Moreover, infecting mice with the LRV1-cured L. 
guyanensis (LgyLRV1-) strain of parasites followed by Type I IFN treatment increased lesion 
size and parasite burden, quantitatively reproducing the LRV1-bearing (LgyLRV1+) infection 
phenotype. This suggested the possibility that exogenous viral infections could likewise 
increase pathogenicity, which was tested by co-infecting mice with L. guyanensis and 
Lymphocytic Choriomeningitis virus (LCMV), or the sand fly-transmitted arbovirus Toscana 
virus (TOSV). The type I IFN anti-viral response increased the pathology of L. guyanensis 
infection, accompanied by down regulation of the IFN-γ receptor normally required for anti-
leishmanial control. Further, LCMV co-infection of IFN-γ-deficient mice promoted parasite 
dissemination to secondary sites, reproducing the LgyLRV1+ metastatic phenotype. 
Remarkably, LCMV co-infection of mice that had healed from L. guyanensis infection 
induced reactivation of disease pathology, overriding the protective adaptive immune 
response. Our findings establish that Type I IFN-dependent responses, arising from 
endogenous viral elements (dsRNA/LRV1), or exogenous co-infection with IFN-inducing 
viruses, are able to synergize with New World Leishmania parasites in both primary and 
relapse infections. Thus, viral infections likely represent a significant risk factor along with 
parasite and host factors, thereby contributing to the pathological spectrum of human 
leishmaniasis. 
 
Significance Statement 
Infection with Leishmania (Viannia) parasites can have different manifestations, 
ranging from localized cutaneous to disseminated and mucocutaneous leishmaniasis, that are 
prone to relapse after the healing. We previously described the association of the 
endosymbiont Leishmania RNA virus 1 (LRV1) with increased disease severity. Here we 
showed that coinfection with the Lymphocytic Choriomeningitis virus (LCMV) or Toscana 
virus exacerbated the outcome of L. guyanensis-induced murine leishmaniasis, favoring 
parasite persistence and dissemination resulting in metastasis. Both endogenous and 
exogenous co-infections were dependent upon Type I interferon responses. Strikingly, LCMV 
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co-infection after the healing of leishmaniasis induced disease reactivation, overriding the 
protective adaptive immune response. Thus, viral infections may be a significant risk factor 
contributing to the pathological spectrum of human leishmaniasis. 
 
Introduction 
Leishmania are protozoan parasites, transmitted as unicellular promastigote forms by 
sand flies to their mammalian host (humans and dogs). In the skin, Leishmania parasites are 
phagocytized by tissue resident macrophages, where they survive intracellularly and 
proliferate as amastigotes. Infection with Leishmania parasites may lead to the development 
of leishmaniasis, affecting over 12 million people worldwide (1, 2). Leishmaniasis may have 
different outcomes, ranging from localized cutaneous leishmaniasis to visceral leishmaniasis 
(1, 2). Infection with L. guyanensis (Lgy) or L. braziliensis (Lbr) principally leads to simple 
cutaneous lesions, however, up to 10% of patients develop disseminated or mucocutaneous 
leishmaniasis. These latter more severe forms of the disease are characterized by the 
dissemination of the parasites from the primary infection site. Another complication of Lgy or 
Lbr infection can be relapse, which may occur months to years after the healing of the 
primary lesion, or after a first line drug treatment (3, 4). Recently, we correlated the 
development of these more severe forms of leishmaniasis with the presence of Leishmania 
RNA virus (LRV1) within different species of Leishmania (3-6). Discovered in the 1980s (7, 
8), and since then for a long time neglected, Leishmaniavirus is a genus of double stranded 
RNA viruses belonging to the Totiviridae family. Like most other viruses in this family, 
LRV1 is neither shed nor infectious, and thus can be seen as a persistent, endogenous viral 
element (9). Two species of LRV have been identified. The LRV1 species is principally found 
in South America within Lgy and Lbr (10, 11), and the LRV2 species is found within L. major 
and L. aethiopica in the Old World (6, 12). The increasing reports of LRVs in different 
Leishmania species could imply a wider role in determining the fate of infection in humans. 
However, in some instances, metastasis and relapse after drug treatment also occur in the 
absence of LRV1 (13). The basis for these discrepancies is of considerable interest, the 
hypothesis put forward include the significance of the presence of other parasite species, 
microbial or host factors that are known to play an important role in the development of MCL 
(14-16). 
The disease-exacerbatory role of LRV1 relies principally on its modulation of the 
innate immune system via its dsRNA genome (5). We recently showed that LRV1-dependent 
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IL-17 promotes the dissemination of the parasite and the consequent formation of metastatic 
lesions (17). Moreover, we demonstrated that LRV1 increases the life span of Lgy-infected 
macrophages through a Toll-like receptor 3 (TLR3) and Akt dependent pathway (18). Further, 
LRV-containing parasites promote TLR3-dependent secretion of pro-inflammatory cytokines 
and chemokines, including interferon-β (IFN-β) (5). Interestingly, ablation of LRV1 using the 
parasite RNAi machinery, or by treatment with compounds selectively inhibiting LRV1, 
completely abrogated the production of pro-inflammatory cytokines by infected macrophages 
(19, 20). 
The induction of TLR3-dependent interferon-β production following infection with 
LRV1+ parasites suggested a potential role in the pathway leading to elevated pathogenicity. 
Type I interferons (Type I IFNs) are mainly known for their anti-viral activity, and interferon 
therapy is currently used to treat several viral infections, including hepatitis B and C and 
herpes virus (21-23). The role of Type I IFNs in bacterial and parasitic infection is less clear, 
as they are known to protect mice from Plasmodium falciparum infection, but on the other 
hand, can promote infection pathology with Listeria monocytogenes, Toxoplasma and 
Trypanosoma (24-27). During parasite infection, Type I IFNs show more variable effects, 
being either protective or detrimental for the host, depending on the dose, timing of 
administration and on the parasite species (28, 29). For L. major, Type I IFNs have been 
associated with control (30-32), whilst for other species,  especially the New World species L. 
amazonensis and Lbr, IFN-β has been associated with promotion of parasite survival and/or 
disease (33-35). 
The potential significance of IFN signaling during infections with Leishmania 
parasites bearing endogenous dsRNA viruses raises the intriguing possibility that co-
infections with exogenous viruses inducing Type I IFNs could also worsen the disease 
outcome. Such co-infections could occur at the site of infection by sand flies carrying both 
Leishmania parasites and Phleboviruses (e.g. TOSV), or by another virus inducing systemic 
production of Type I IFNs. Thus far little is known about co-infection with Leishmania and 
viruses, with the exception of HIV and the phenotypic change due to its impairment of the 
adaptive immune response (16, 36). 
In this study, we investigated the disease exacerbatory role of viral-induced Type I 
IFNs in Lgy infection, not only with LRV1-bearing Lgy (LgyLRV1+), but also by co-infecting 
mice with LRV1-cured Lgy (LgyLRV1-) and Lymphocytic Choriomeningitis virus (LCMV), or 
Toscana virus (TOSV).  
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 Results 
Type I IFNs exacerbate LgyLRV1+ infection  
We first analyzed whether Type I IFNs could modulate the pathogenicity of Lgy. 
C57BL/6 wild type (WT) or Type I IFN receptor deficient (ifnar-/-) mice were infected with 
LgyLRV1- or LgyLRV1+ parasites. Two weeks post infection, WT mice began to develop 
lesions that grew until reaching a maximal size at week 5 which then healed 4 weeks later, 
with LgyLRV1+ infection inducing significantly larger lesions compared to LgyLRV1- 
infected mice (Fig. 1A). In contrast, LgyLRV1+ infected ifnar-/- mice developed significantly 
smaller lesions, similar to those developed by ifnar-/- and WT mice infected with LgyLRV1- 
(Fig. 1A). Parasite numbers were also significantly increased in WT mice infected with 
LgyLRV1+ compared to the LgyLRV1- infected counterpart (Fig. 1B). Again, no difference 
was observed between ifnar-/- mice, independent of the presence of LRV1 in the infecting 
parasite, as the parasite load was similar to LgyLRV1- infected WT mice. Thus, the 
deleterious effect of Type I IFNs includes worsening of lesion pathology and increased 
parasite numbers.  
To further confirm the deleterious role of Type I IFNs, WT mice were injected with 
recombinant IFN-β (IFN-β) at early time points post Lgy infection, to mimic the anti-viral 
response induced by the endogenous dsRNA LRV1 virus (5). In LgyLRV1- infected mice, 
IFN-β showed a dose-dependent effect in increasing the lesion size and the parasite load at the 
peak of infection. In fact, injection of 100U of IFN-β showed a moderate increase in lesion 
size and no effect on parasite load, whereas injection of 500U or 1000U caused greater 
increase of both lesion size and parasite burden, quantitatively reproducing the phenotype of 
LgyLRV1+ infection (Fig. 1C-D). In contrast, little effect from IFN-β treatment was seen in 
LgyLRV1+ infected mice, (Fig. 1E-F). Similar results were obtained with IFN-α treatment 
(Fig. S1).   
 
Viral co-infection increases the severity of Lgy leishmaniasis 
The data above, in combination with previous findings (5), suggest that the 
endogenous dsRNA virus LRV1 acts to promote Lgy virulence through TLR3 and Type I 
interferon signaling. This alluded to the possibility that other agents triggering Type I 
interferon responses might act similarly to promote Leishmania virulence, such as co-
infections with other viruses. To test this, we co-infected mice with LgyLRV1- parasites and 
lymphocytic choriomeningitis virus Armstrong (LCMV), an arenavirus which induces a 
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potent Type I IFN response (37). Two different sites of injection were used, intra-peritoneal 
injection for LCMV and subcutaneous in the footpad for Lgy.  
Infection with LCMV Armstrong was shown to be cleared in 8 days by C57BL/6 WT 
mice with a robust T cell response (38). Viral titration in mouse serum, following 
intraperitoneal inoculation, showed only transient and very low viremia (39). As previously 
reported (40), the presence of Leishmania parasites did not increase LCMV infection (Fig. 
S2). Similarly, the concentration of Type I IFNs in the serum after 24 hours of LCMV 
infection was comparable between mice infected or not with Lgy (Fig. S3). These data 
demonstrated that the development of the LCMV infection was not affected by the presence 
of Lgy parasites. Interestingly, Type I IFNs were not detected in mouse blood following single 
infection with LgyLRV1+, suggesting that in this particular case the Type I IFN response is 
only local (Fig. S3). 
We subsequently investigated whether LCMV-induced Type I IFNs stimulated gene 
expression at the site of Leishmania infection. We observed that genes known to be 
stimulated by Type I IFNs (oas1a, oas2, oasl2 or pkr) were significantly up-regulated in mice 
infected with LgyLRV1+, or with LgyLRV1- co-infected with LCMV, compared to LgyLRV1- 
infected mice (Fig. S3).  
We then tested the effect of LCMV co-infection on the progression of leishmaniasis. 
LCMV injection in LgyLRV1- infected mice significantly worsened the outcome of 
leishmaniasis, increasing both pathology and parasite burden, which were very similar to the 
phenotype induced by LgyLRV1+ infection (Fig. 2A and C). The LCMV aggravation of Lgy-
induced leishmaniasis completely relied on Type I IFNs, as no difference was observed when 
LCMV was injected into LgyLRV1- infected ifnar-/- mice, neither with regard to footpad 
swelling nor parasite burden. ifnar-/- mice failed to rapidly clear the virus due to the absence 
of a proper Type I IFN response (Fig. S2) (41). Moreover, this effect could again be related to 
the Type I IFN level, since, as already shown in the Type I IFNs injection experiment, no 
significant effect was observed when LCMV was injected in LgyLRV1+ infected mice (Fig. 2 
B and D). 
We furthermore asked if another virus could similarly affect the course of 
leishmaniasis. We focused on Toscana virus (TOSV), a phlebovirus transmitted to humans by 
the same insect vector as Leishmania parasites (42). Mimicking the likely biological route of 
concomitant infection, TOSV was inoculated together with Lgy parasites subcutaneously into 
the footpad. As observed with LCMV, LgyLRV1-/TOSV co-infection highly increased 
footpad swelling and parasite burden at the peak of infection (Fig. 2E-F). ifnar-/- mice were 
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susceptible to TOSV infection, with over 50% of mortality after two weeks of infection, 
precluding further tests on the Type I IFN dependency in this co-infection model. 
 
Viral co-infection modulates macrophage responsiveness to IFN-γ through Type I IFNs 
The data above suggested that co-infection with exogenous RNA viruses resulted in 
worsening of leishmaniasis, quantitatively similar to that seen by parasites bearing 
endogenous LRV1. We thus focused on defining potential mechanisms responsible for these 
exacerbated phenotypes. The immune system efficiently clears intracellular Leishmania 
through the production of IFN-γ (43), and Type I interferon responses are known to down-
modulate IFN-γ responses (24). The early IFN-γ response is fundamental for the 
determination of the outcome of Leishmania infection (44), consistent with our finding 
showing that injection of Type I IFNs in the first hours of infection is crucial for the 
development of  disease (Fig. 1C-D). As LRV1 or LCMV co-infection did not modulate early 
IFN-γ production (Fig. S4), we wondered if IFN-γ signaling was modulated during co-
infections. To this end, we firstly, measured IFN-γR surface expression on bone marrow 
derived macrophages. Infection with LgyLRV1+ parasites induced a significant down-
regulation of IFN-γR compared to LgyLRV1-, in a Type I IFN dependent manner (Fig. S5). In 
this in vivo model of co-infection with LCMV and Leishmania, the pathogens were inoculated 
at two different sites, lowering the chances for the same cell to be infected by both pathogens 
and arguing for a systemic production of Type I IFNs. Thus, in in vitro experiments we 
replaced LCMV co-infection by treating the cells with increasing doses of recombinant IFN-α 
or IFN-β subsequent to LgyLRV1- infection. Both Type I IFNs induced IFN-γR down-
regulation in a dose-dependent manner, with IFN-β showing somewhat higher potency 
(somewhat greater than 2 fold; Fig. S5D). Subsequently, we confirmed these results during in 
vivo infection. Flow cytometric analysis 48 hours post infection showed that macrophages 
from LgyLRV1+ infected, or LgyLRV1-/LCMV infected mice, expressed significantly lower 
levels of surface IFN-γ-receptor (IFN-γR), compared to infections by LgyLRV1- alone (Fig. 
3A). No significant difference was observed in ifnar-/- mice (Fig. 3B), however, the down-
regulation of IFN-γR expression was observed when mice were infected with LgyLRV1- and 
injected with IFN-α or IFN-β (Fig. 3C). This confirmed that the effect depended on Type I 
IFNs. 
 
LCMV – Lgy co-infection accelerates parasite dissemination 
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The importance of IFN-γ was further demonstrated as a critical component of our 
murine model for metastatic leishmaniasis, where IFN-γ-/- mice failed to control Lgy 
infection, causing multiple metastatic lesions, usually located on the tail (17). In this model, 
metastases were accelerated in the presence of the endogenous LRV1 within Lgy parasites. 
Interestingly, IFN-γ-/- mice co-infected with LgyLRV1-/LCMV developed metastasis earlier 
than those infected with LgyLRV1- alone, thus reproducing the phenotype of LgyLRV1+ 
parasites. Therefore, exogenous viral co-infection was equally capable of synergizing parasite 
virulence and metastasis (Fig. 4A-C). 
 
LCMV infection induces reactivation of leishmaniasis 
We then asked whether viral infection could lead to reactivation of leishmaniasis 
following healing, a pathological situation often observed in humans (45). LCMV injection 
subsequent to lesion healing induced reactivation of the disease, with a reappearance of both 
lesion pathology and increased parasite numbers, overriding the protective adaptive immune 
response essential in C57BL/6 mice re-infected with Lgy (Fig. S6). Once reactivated, 
pathology and parasite burden progressed very similarly to that seen in concomitant LgyLRV1-
/LCMV infections, with the lesion pathology and size peaking around 5 weeks post LCMV 
injection and healing a few weeks later (Fig. 5A). Further, at the peak of LCMV infection, we 
found higher parasite burden, a sign of reactivation of parasite proliferation (Fig. 5B). The 
mechanism of relapse relied on Type I IFNs, since no footpad swelling or increase in parasite 
load was observed in ifnar-/- mice infected with either LgyLRV1- or LgyLRV1+ (Fig. 5A-B). 
As seen with simultaneous infections, the subsequent delayed post-healing LCMV injection in 
LgyLRV1- infected mice induced down-regulation of IFN-γR surface expression on 
macrophages in a Type I IFN-dependent manner (Fig. S7A). 
Interestingly, LgyLRV1+ infected WT mice developed only small lesions and parasite 
number compared to their LgyLRV1- counterparts, thus reversing the phenotype observed in 
simple Lgy infection. Indeed, when LgyLRV1- infected mice were injected with Type I IFNs 
during the first two days of infection, they developed less severe relapses when subsequently 
co-infected with LCMV (Fig. 5C). This result suggests that early Type I IFN production could 
significantly prevent the reactivation of the disease in mice previously infected with 
LgyLRV1+, thus explaining the difference between the LgyLRV1+ and LgyLRV1- relapsing 
phenotype. Accordingly, the down-regulation of IFN-γR was not observed in LgyLRV1+ 
	 9	
infected, nor in LgyLRV1-/ Type I IFN injected mice (Fig. S7B), suggesting that early Type I 
IFN signaling may inhibit the effect of a subsequent LCMV co-infection.  
 
Discussion 
In this study we confirmed in an in vivo murine model of leishmaniasis that the 
detrimental role of LRV1 borne by Lgy was due to the anti-viral response triggered by viral 
dsRNA recognition, which culminated in Type I IFN production. Further, we demonstrated 
that injection of recombinant Type I IFNs during the initial days of infection was sufficient to 
worsen the outcome of leishmaniasis. Despite the fact that Type I IFNs are mainly known for 
their anti-viral role, increasing evidence attests the involvement of Type I IFNs in bacterial 
and parasitic infection (24-27, 29). Our findings are consistent with earlier reports suggestive 
of a disease exacerbatory role for Type I interferons in New World Leishmania species (33-
35). 
Here we showed that LgyLRV1+ infection, or LgyLRV1- plus LCMV co-infection, 
induced the down-regulation of IFN-γR on macrophages, in a Type I IFN dependent manner. 
In this model both Type I IFNs demonstrated activity, with IFN-β showing greater potency in 
vitro.  The importance of IFN-γ production during the first days of infection with Leishmania 
parasites has been widely described (44). In our model of co-infection we did not observe 
differences in early IFN-γ production, nevertheless the lower expression of the IFN-γ receptor 
likely acts to promote the development of disease. Recently we have shown that infection 
with LgyLRV1+ highly increased macrophage survival in vitro (18). This result, combined 
with the down-regulation of IFN-γR, suggests that the presence of viral co-infection increased 
the persistence of Leishmania parasites. While the down-regulation of IFN-γR was 
quantitatively modest, this was also observed in studies of the exacerbatory role of Type I 
interferons in Listeria infections (24). Our studies, however, do not rule out other mechanisms 
of disease exacerbation induced by Type I IFNs.  
Significantly, exogenous viral co-infection with LCMV or TOSV worsened the 
outcome of murine leishmaniasis caused by LgyLRV1-, reproducing the phenotype of 
LgyLRV1+ infected mice (Fig. 2). It was recently reported that mice infected with LCMV 
present increased lesions when subsequently infected with L. major (46). This phenotype was 
due to an increased inflammatory response induced by memory T cells not accompanied by 
an increased parasite burden. Similar results were observed when mice were firstly infected 
with L. major and only two weeks later co-infected with LCMV (40). In this latter case, a 
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transiently decreased anti-Leishmania immune response was observed one week following 
LCMV co-infection. In our experiments, mice were infected at the same time with parasites 
and LCMV, leading not only to increased footpad lesions, but also to higher parasite burden, 
compared to infection with parasites alone. This suggests that there was a decrease of 
macrophage anti-parasitic activity, consistent with the lower IFN-γR expression on 
macrophages, this observation, however, did not exclude other possible systemic effects of 
LCMV. Interestingly, LCMV co-infection was able to promote the metastatic phenotype in 
LgyLRV1- infected IFN-γ-deficient mice (Fig. 4). Further, we showed that disease 
exacerbation of LRV1 and LCMV co-infection depended completely on Type I IFNs (Fig. 
2A-B).  
These findings may explain why the tight correlation between disease severity and 
metastasis with LgyLRV1+ in animal models (5) may be more variable in humans (13, 17, 47, 
48). Potentially, co-infection with viruses or other pathogens inducing a sufficient amount of 
Type I IFNs could increase the severity of Lgy infection, contributing to the development of 
more severe disease manifestations. Certainly, many viral diseases are found in Leishmania 
endemic regions which could contribute to increased disease severity (49). A number of 
arboviruses are transmitted by the sand fly vectors also transmitting Leishmania, including the 
Massilia and TOSV Phleboviruses (50, 51). Co-infection was reported in dogs, while 
seropositivity to TOSV was associated with L. infantum in humans (52, 53), however, the 
clinical relevance of the co-infection is unknown. Since our results suggest that events early 
in infection were crucial to determine the fate of the disease (Fig 1C-D), having the virus 
transmitted simultaneously with Leishmania (Viannia) could magnify the impact of 
coinfection. However, intraperitoneal LCMV infections which induce a systemic Type I IFN 
response strongly exacerbated disease, suggesting that co-infections do not require the same 
entry site.   
Finally, we showed that LCMV infection following the resolution of the primary 
lesion induced relapses of leishmaniasis, overriding the memory immune response of the host. 
Surprisingly, relapses were more severe in LgyLRV1- infected mice compared to LgyLRV1+. 
This result correlated with a Type I IFN dependent down-regulation of IFN-γR observed in 
LgyLRV1- infected mice compared to LgyLRV1+, confirming the role of IFN-γR in 
determining the outcome of the disease. Identification of the mechanism(s) underlying 
difference will require future investigation. In humans, relapses are observed following 
infection with different species of Leishmania and can have varying outcomes, ranging from a 
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simple cutaneous lesion, to DCL or MCL in the case of Lgy or Lbr infection, or post-kala-azar 
dermal leishmaniasis, in the case of L. donovani  infection (3, 54, 55). Here we suggest that 
viral co-infection and prior exposure to Type I IFNs could not only be a risk factor for 
relapses of leishmaniasis, but could be the trigger of parasite reactivation.  
In total, our findings establish a major role for simultaneous or subsequent viral 
infection in determining the severity of Leishmania (Viannia) infection in animal models and 
that viral co-infections could contribute towards metastasis and relapse in human patients 
suffering from leishmaniasis. 
  
Material and Methods 
 
For additional information please refer to the SI text. 
 
Mice 
C57BL/6 WT mice were purchased from Harlan Laboratories (Netherlands), type-1 IFN 
receptor deficient (ifnar-/-) mice were obtained from M. Aguet, Swiss Institute of 
Experimental Cancer Research (Epalinges, Switzerland), IFN-γ-/- mice were purchased from 
Jackson laboratories. Experimentation procedures were undertaken with strict adherence to 
ethical guidelines set out by the Swiss Federal Veterinary Office and under inspection by the 
Department of Security and Environment of the State of Vaud, Switzerland.  
 
Parasites and viruses Matched	 LgyLRV1+	 and	 LgyLRV1-	 parasites	 expressing	 luciferase	 obtained	 following	limited	 treatment	 with	 anti-LRV1	 inhibitors	 were	 used	 in	 all	 studies	 (20).	 In vivo 
parasites were quantified by luciferase bioluminescence imaging as described previously (17).  
LCMV and TOSV were provided by D. Zehn and M. G. Cusi, respectively. 
 
Macrophages 
Bone marrow derived macrophages were generated as described previously (18). 
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Figures 
 
Figure 1. Type I IFNs increased the severity of Lgy infection. 
(A-B) WT or ifnar-/- mice were infected in the hind footpads with 3 x 106 stationary phase 
Lgy promastigotes. (C-F) At 6, 24 and 48 hours post infection (p.i.) WT mice were injected 
with the indicated amount of IFN-β into the footpad. (A, C and E) Footpad thickness was 
measured weekly. (B, D and F) Parasite burden was quantified 5 weeks p.i. in vivo by 
measuring parasite bioluminescence. Results of one representative of 3 independent 
experiments were expressed as mean ± SEM (n=5). Statistical significance was assessed by 
Repeated measure ANOVA (A, C and E), Two-way ANOVA (B) or Student’s t-test (D and F) 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure 2. Viral co-infection increased the severity of leishmaniasis through Type I IFNs. 
(A-F) WT or ifnar-/- mice were infected in the hind footpads with 3 x 106 stationary phase 
Lgy promastigotes. (A-D) Leishmania infected mice were injected simultaneously with 2 x 
105 PFU of LCMV Armstrong or the same volume of PBS as vehicle control intra-
peritoneally. (E-F) Alternatively, Leishmania infected mice were simultaneously inoculated 
with 5 x 105 PFU of TOSV subcutaneously into the footpad. (A, B and E) Footpad thickness 
was measured weekly. (C, D and F) Parasite burden was measured 5 weeks p.i. by measuring 
parasite bioluminescence or by RT-qPCR. Results of one representative of 3 independent 
experiments were expressed as mean ± SEM (n=5). Statistical significance was assessed by 
Repeated measure ANOVA (A, B and E) or Two-way ANOVA (C, D and F) **p<0.01, 
***p<0.001. 
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Figure 3. Lgy - LCMV co-infection modulated IFN-γR expression on macrophages 
through Type I IFNs. 
(A) WT or (B) ifnar-/- mice were infected in the hind footpads with 3 x 106 stationary phase 
Lgy promastigotes. At the same time, where indicated, mice were injected intra-peritoneally 
with 2 x 105 PFU of LCMV Armstrong. (C) Alternatively, at 6 hours p.i., LgyLRV1- infected 
WT mice were injected with 1’000U of IFN-α or IFN-β subcutaneously into the footpad. 
Forty-eight hours p.i., popliteal LN cells were recovered and IFN-γ receptor expression at the 
surface of macrophages was measured by flow cytometry. Results of one representative of 3 
independent experiments were expressed as mean ± SEM (n=5). Statistical significance was 
assessed by Two-way ANOVA (A-B) or Student's t-test (C) *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4. Lgy - LCMV co-infection promoted disease dissemination. 
(A-C) IFN-γ-/- mice were infected in the hind footpads with 3 x 106 stationary phase Lgy 
promastigotes. At the same time, where indicated, mice were injected intra-peritoneally with 
2 x 105 PFU of LCMV Armstrong. (A) Footpad thickness was measured weekly. (B) Number 
of metastatic lesions per mouse at week 7, 8 and 9 p.i.. (C) Image of photo of representative 
mice showing metastatic lesions on the tail at week 8 post infection. Results of one 
representative of 3 independent experiments were expressed as mean ± SEM (n=5). Statistical 
significance was assessed by Repeated measure ANOVA (A) or Two-way ANOVA (B), 
*p<0.05, **p<0.01. 
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Figure 5. LCMV late co-infection induced the relapse of leishmaniasis. 
(A-B) WT or ifnar-/- mice were infected in the hind footpads with 3 x 106 stationary phase 
Lgy promastigotes. (C) At 6, 24 and 48 hours p.i., LgyLRV1- infected WT mice were injected 
with 1’000U of IFN-α or IFN-β. After the healing, mice were injected intra-peritoneally with 
2 x 105 PFU of LCMV Armstrong. (A and C) Footpad thickness was measured weekly. (B) 
Parasite burden was measured at week 17 p.i. by RT-qPCR, measuring kmp11 gene 
expression. Results of one representative of 3 independent experiments were expressed as 
mean ± SEM (n=5). Statistical significance was assessed by Repeated measure ANOVA (A 
and C) or Student's t-test (B) *p<0.05, **p<0.01, ***p<0.001. 
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Supporting Information 
 
SI text 
 
LgyLRV1+ infection induced Type I IFN expression in vivo 
We previously demonstrated that macrophages produce IFN-β upon infection with 
LgyLRV1+ parasites in vitro (5). To verify if similar production was occurring in vivo, 
C57BL/6 WT mice were inoculated with LgyLRV1+ or LgyLRV1- parasites in the hind 
footpad. At 6 or 12 hours post infection, mice were sacrificed, and the footpads and draining 
lymph nodes were recovered and used for RT-qPCR analysis. ifn-β transcription was up-
regulated at early time points post LgyLRV1+ infection in both footpads and draining lymph 
nodes (Fig. S8). The increase of transcription was found to be only transient, as 48 hours post 
infection, Type I IFNs were not detectable neither in the lymph node, nor in the footpad. 
Similar results were obtained for ifn-α (Fig. S8). Further, in vivo macrophage depletion using 
clodronate-containing liposomes completely abrogated the induction of ifn-α and ifn-β, 
demonstrating that macrophages are responsible for Type I IFN production in LgyLRV1+ 
infection (Fig. S8 and S9). 
 
SI Material and methods 
 
Mice 
Four to 5 week old C57BL/6 mice were purchased from Harlan Laboratories 
(Netherlands), Type I IFN receptor deficient (ifnar-/-) mice were obtained from M. Aguet, 
Swiss Institute of Experimental Cancer Research (Epalinges, Switzerland), IFN-γ-/- mice 
were purchased from Jackson laboratories. Mice were kept and bred at the animal facility of 
the Center of Immunity and Immunology, Lausanne (Switzerland) in a pathogen-free 
environment. All animal protocols were approved by the Swiss Federal Veterinary Office 
(SFVO), under the authorization numbers 2113.1, 2113.2a and 2113.2b. Animal 
experimentation procedures were undertaken with strict adherence to ethical guidelines set 
out by the SFVO and under inspection by the Department of Security and Environment of the 
State of Vaud, Switzerland. 
 
Parasites 
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LRV1-bearing and LRV1-cured L. guyanensis parasites (LgyLRV+ and LgyLRV- 
respective) were used in all studies. These parasites were obtained following brief drug 
treatment of the LRV1+ strain of L. guyanensis M4147 containing a firefly luciferase (ffLUC) 
gene integrated stably into the small subunit gene of the ribosomal RNA locus 
(LgM4147/SSU:IR2SAT-LUCb LRV1+) as described previously (20). 
Parasites were cultured at 26°C in Schneider’s medium (Sigma-Aldrich) supplemented with 
10% Fetal Calf Serum (FCS), 1% penicillin/Streptomycin (P/S), 1% HEPES (Sigma-Aldrich), 
0.6 µg/ml of Biopterin (Sigma-Aldrich) and 5 µg/ml of Haemin (Sigma-Aldrich). 
 
Viruses 
Lymphocytic choriomeningitis virus (LCMV) 53b Armstrong was provided by Prof. 
Dietmar Zehn (Technical University of Munich, Germany). The LCMV 53b Armstrong strain 
was propagated in baby hamster kidney cells and titrated on Vero African green monkey 
kidney cells according to an established protocol (56). Frozen stocks were diluted in PBS; 
2x105 plaque-forming units (PFU) of LCMV Armstrong were injected intra-peritoneally. 
Blood samples from LCMV-infected mice were 'shock frozen' to release the virus. Diluted 
samples were used for infection of Vero cells, and viral titers were determined by the LCMV 
focus-forming assay. 
Toscana virus strain 1812 (TOSV) was provided by Maria Grazia Cusi (University of 
Siena, Italy). TOSV was propagated and titrated on Vero cells according to an established 
protocol (57). 5x105 PFU of TOSV in 50µl of PBS was inoculated subcutaneously into the 
footpad. 
 
Mice infection 
Stationary phase parasites were injected into the hind footpads of mice at a 
concentration of 3x106 parasites per footpad in 50µl of PBS. Footpad thickness was measured 
weekly post infection (p.i.) using a Vernier caliper. Where required, mice were injected in the 
footpad at 6, 24 and 48 hours p.i. with the indicated amount of murine recombinant interferon 
beta (IFN-β, CellScience), or interferon alpha (IFN-α, CellScience) in 50µl of PBS, or with 
the same volume of PBS as vehicle-control. 
 
Macrophage extraction and culture 
In order to obtain bone marrow derived macrophages (BMDMs), bone marrow was 
extracted from tibias and femurs of C57BL/6 or ifnar-/- mice. Macrophages were cultured at 
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37°C and 5% CO2 in 10ml of Dulbecco’s modified eagle medium (DMEM, Gibco®) 
supplemented with 10% of Fetal Calf Serum (FCS), 1% of P/S, 1% of HEPES (Sigma-
Aldrich) and 50ng/ml of murine recombinant M-CSF (Immunotools). After 3 days, 5ml of 
fresh DMEM medium was added to the culture and 3 days later BMDMs were used for 
stimulation assays. 
 
IFN-γ receptor measurement 
5 x 105 BMDMs in 200µl of DMEM supplemented with 10% FCS, 1% P/S, and 1% 
HEPES (DMEM complete medium) were seeded in a 48 well plate and incubated at 37°C and 
5% CO2 O/N. BMDMs were subsequently infected with L. guyanensis parasites (Lgy) 
(multiplicity of infection (moi) 3:1) in 200µl of DMEM complete medium. At 6 hours p.i., 
BMDMs were treated with 50, 100, 250, 500 or 1000U/ml of murine recombinant IFN-α or 
IFN-β (CellScience). Forty-eight hours p.i., BMDMs were detached with PBS/5mM EDTA 
and IFN-γR surface expression was measured by FACS.  
To measure IFN-γR expression in vivo, mice were infected with L. guyanensis 
parasites and co-infected with LCMV, or treated with IFN-α, or IFN-β as described above. 
Mice were sacrificed at 48 hours p.i. and popliteal lymph node cells were recovered. IFN-γR 
expression on macrophages was measured by flow cytometry using the following antibodies: 
IFN-γR1-PE (clone 2E2, dilution 1:100), CD11b-FITC (clone M1/70, 1:500), CD11c-PECy7 
(clone N418, 1:500) and F4/80-APC (clone BM8, 1:300) (ebioscience). Flow cytometry was 
performed with a BD Accuri™ C6 cytometer and results were analyzed using FlowJo 
Software (Tree Star). 
 
IFN-γ  measurement in vivo 
WT mice were infected with L. guyanensis parasites and co-injected with LCMV or 
PBS as control as described above. Mice were sacrificed at 48 hours p.i., popliteal lymph 
node cells were subsequently recovered and intracellular expression of IFN-γ within NK, 
CD4T and CD8T cells was measured by flow cytometry, using the following antibodies: 
CD3-APC-Cy7 (clone 17A2, dilution 1:1000), CD4-Pacific blue (clone GK1.5, 1:1000), 
CD8-PerCP (clone 53-6.7, 1:1000)(BioLegend), NK1.1-FITC (clone PK136, 1:500), IFN-γ-
PE (clone XMG1.2, 1:500)(ebioscience). Flow cytometry was performed with a BDTM LSR-II 
flow cytometer (BD Biosciences) and results were analyzed using FlowJo Software (Tree 
Star). Alternatively, popliteal lymph node cells were cultured for 72 hours in complete 
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DMEM medium. After 72 hours, cells were pelleted and supernatant was recovered. IFN-γ 
protein concentration was measured by ELISA using an IFN-γ ELISA kit (ebioscience) 
following manufacturer’s instructions. 
 
Type I Interferon and Interferon stimulated gene measurement 
Transcript levels of ifn-α and ifn-β were measured in vivo in footpads and draining 
lymph nodes (LNs), at 6 and 12 hours p.i., respectively. Alternatively, transcript levels of 
ISGs were measured in vivo in draining LNs at 24 hours p.i.. To allow RNA extraction, LNs 
were stored in RNAlater RNA stabilization solution (Quiagen) whereas footpads were frozen 
and then homogenized in TRIzol (Life Technologies). Total RNA was extracted from LNs 
and footpads using the ZR-96 RNA Clean & Concentrator™ (Zymo research), and cDNA 
was generated using SuperScript II Reverse Transcriptase (Invitrogen™). The cDNA obtained 
was purified with the ZR-96 DNA Clean & Concentrator™-5 (Zymo research). Real-Time 
Quantitative PCR (qRT-PCR) was performed using the LightCycler 480 (Roche Applied 
Science) to measure SYBR green (Lightcycler®480 SYBR Green I Master, Roche) 
incorporation. The following primers were used: ifn-α: 5'-
GGACTTTGGATTCCCGCAGGAGAAG and 5'-GCTGCATCAGACAGCCTTGCAGGTC; 
ifn-β: 5'-AACCTCACCTACAGGGC, and 5'-CATTCTGGAGCATCTCTTGG; l32: 5'-
AAGCGAAACTGGCGGAAAC and 5'-TAACCGATGTTGGGCATCAG; oas1a: 5’-
CCCATCTGCATCAGGAGGTG and 5’-GGATCAGGCTTGCTGGAAGT; oas2: 5’-
TGAAGAAGCGAAGGAGTGGC and 5’-GGGTCTGCATTACTGGCACTT; oasl2: 5’-
CCGCGACATCTGCATCTACT and 5’-CGGTCTCCCTTCAGCTGTTT; pkr: 5’-
CAGAAACTTTGGCCACTGGGA and 5’-CCGTGCATCTGGCGGTATT. The results were 
analyzed using the CT method (2-ΔΔCt) for relative quantification of gene expression and 
normalized to l32. The fold induction was calculated according to the relative expression in 
naive mice. 
Type I interferon protein levels were measured 24 hours p.i. in mice serum, using the 
Verikine mouse IFN-α ELISA Kit and Verikine-HS Mouse IFN-β Serum ELISA Kit (PBL 
assay science), following manufacturer’s instructions. 
 
Parasite quantification 
In vivo parasites were quantified at the peak of infection in mouse footpads by 
injecting 15mg/kg of luciferin (Invivo Imaging) intra-peritoneally and measuring the 
luminescence produced in the footpads with a Xenogen IVIS Lumina II. The following 
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parameters were used: exposure 10 minutes, binning medium, F/stop 1.2. Alternatively, the 
Brucker Extreme II machine was used with the following parameters: exposure 5 minutes, 
binning 4, F/stop 1.2.  
 
Macrophage depletion 
To deplete macrophages from the draining lymph nodes, WT mice were injected 
subcutaneously into the ankle with 50µl of PBS- or Clodronate-containing liposomes 
(ClodronateLiposomes.org). Three weeks post-treatment, mice were infected with 3x106 
stationary phase L. guyanensis parasites in each footpad. Mice were sacrificed 12 hours p.i., 
draining LNs were taken and macrophage presence was measured by FACS using the 
Accuri® cytometer C6 and data analyzed with FlowJo (version 10.0.7). The following 
antibodies were used: CD169-PE (clone 3D6.112), CD11b-FITC (clone M1/70) and CD11c-
PEcy7 (clone N418) (ebioscience). 
 
Statistical analysis 
Data obtained from Xenogen and FACS were analyzed using either two-way ANOVA 
or Student's t-test. Data obtained from qRT-PCR and ELISA were analyzed using a Student's 
t-test. Data obtained from footpad swelling measurements were analyzed using a repeated 
measure ANOVA test. When the curves were non-parallel (i.e. the treatment-time interaction 
was statistically significant), statistical significance of difference between treatments at 
different time points was assessed using Bonferroni’s multiple test correction. 
Statistical significance was set at a p-value lower than 0.05. All data are represented 
with the mean ± the standard error of the mean (SEM).  All analyses were performed using 
GraphPad Prism® software. 
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SI Figures 
 
 
Figure S1. IFN-α injection increased the size of the lesions of LRV1-Lgy infected mice. 
WT mice were infected in the hind footpads with 3 x 106 stationary phase Lgy promastigotes. 
At 6, 24 and 48 hours p.i., mice were injected with increasing doses of IFN-α subcutaneously 
into the footpad. (A and C) Footpad thickness was measured weekly. (B and D) Parasite 
burden was quantified 4 weeks p.i. in vivo by measuring parasite bioluminescence. Results of 
one representative of 2 independent experiments were expressed as mean ± SEM (n=5). 
Statistical significance was assessed by Repeated measure ANOVA (A and C) or Student’s t-
test (B and D) ***p<0.0001. 
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Figure S2. Leishmania co-infection did not affect LCMV clearance. 
(A) WT or (B) ifnar-/- mice were infected intra-peritoneally with 2 x 105 PFU of LCMV 
Armstrong. At the same time, where indicated, mice were injected in the hind footpad with 3 
x 106 stationary phase Lgy promastigotes. LCMV titer in the blood was measured at different 
times p.i. by plaque assay. Results of one experiment were expressed as mean ± SEM (n=5). 
Statistical significance was assessed by Repeated measure ANOVA. 
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Figure S3. LRV1 and LCMV co-infection induced a similar interferon response in vivo. 
WT mice were infected in the hind footpad with 3 x 106 stationary phase Lgy promastigotes, 
or PBS as control. At the same time, where indicated, mice were injected intra-peritoneally 
with 2*105 PFU of LCMV Armstrong. (A) IFN-β and (B) IFN-α concentration in serum was 
measured by ELISA 24 hours p.i.. (C-F) Popliteal LNs were recovered 24 hours p.i. and used 
for RT-qPCR analysis. Results of one representative of 2 independent experiments were 
expressed as mean ± SEM (n=5) of protein concentration (A-B) or as mean ± SEM (n=5) of 
transcript increase relative to LgyLRV1- infected mice, and normalized to housekeeping gene 
l32 (C-F). Statistical significance was assessed by Student’s t-test, ***p<0.001. 
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Figure S4. LRV1 or LCMV co-infection did not modulate early IFN-γ  production in 
vivo. 
WT mice were infected in the hind footpad with 3 x 106 stationary phase Lgy promastigotes. 
At the same time, where indicated, mice were injected intra-peritoneally with 2*105 PFU of 
LCMV Armstrong, or PBS as control. Popliteal LN cells were recovered 48 hours p.i.. (A) 
Flow cytometry dot plots showing intracellular IFN-γ expression in different cell populations. 
(B-D) Frequency of IFN-γ-expressing NK, CD8T and CD4T cells, respectively. Results of 
one experiment were expressed as mean ± SEM (n≥4). (E) IFN-γ secretion by lymph node 
cells was measured by ELISA. Results of a pool of two independent experiments were 
expressed as mean ± SEM (n=8). Statistical significance was assessed by Student’s t-test, 
results were non-significant. 
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Figure S5. LgyLRV1+ infection or Type I IFN treatment down-regulated IFN-γR 
expression on macrophages. 
WT BMDMs were infected with Lgy parasites. Six hours p.i., LgyLRV1- infected 
macrophages were treated with 1’000U/ml of IFN-α or IFN-β. Forty-eight hours p.i., IFN-γR 
expression was measured by flow cytometry. Results of one representative of 3 independent 
experiments showed IFN-γR surface expression on LgyLRV1+ infected (A), IFN-α (B), or 
IFN-β (C) treated macrophages compared to LgyLRV1- infection. (D) WT BMDMs were 
infected with Lgy parasites. Six hours p.i., LgyLRV1- infected macrophages were treated with 
increasing doses of IFN-α or IFN-β (50, 100, 250, 500 or 1’000U/ml). Forty-eight hours p.i., 
IFN-γR expression was measured by flow cytometry. Results of a pool of 2 independent 
experiments were expressed as mean ± SEM of IFN-γR MFI. Statistical significance was 
assessed by Student's t-test (D) *p<0.05, **p<0.01, ***p<0.001. 
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Figure S6. C57BL/6 WT mice are protected against Lgy re-infection. 
WT mice were infected in the hind footpad with 3 x 106 stationary phase Lgy promastigotes. 
Twelve weeks p.i. mice were re-infected with Lgy promastigotes. (A) Footpad thickness was 
measured weekly. (B) Parasite burden was quantified 15 weeks p.i. in vivo by measuring 
parasite bioluminescence. Results of one representative of 2 independent experiments were 
expressed as mean ± SEM (n=5). Statistical significance was assessed by Student’s t-test, 
results were non-significant. 
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Figure S7. Early Type I IFNs inhibited IFN-γR down-regulation following LCMV co-
infection. 
(A) WT or ifnar-/- mice were infected in the hind footpads with 3 x 106 stationary phase Lgy 
promastigotes. (B) At 6, 24 and 48 hours p.i., LgyLRV1- infected WT mice were injected with 
1000U of IFN-α or IFN-β. After the healing, mice were injected intra-peritoneally with 2 x 
105 PFU of LCMV Armstrong. (A-B) Forty-eight hours after LCMV infection, popliteal LN 
cells were recovered and IFN-γ receptor expression on macrophages was measured by FACS.  
Results of one representative of 2 independent experiments were expressed as mean ± SEM 
(n=5). Statistical significance was assessed by Two-way ANOVA (A) or Student's t-test (B) 
*p<0.05, ***p<0.001. 
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Figure S8. LgyLRV1+ parasite infection induced Type I IFN up-regulation in vivo. 
WT mice were infected in the hind footpads with 3 x 106 Lgy stationary-phase promastigotes. 
ifn-β and ifn-α transcript levels were quantified by RT-qPCR at 6 or 12 hours p.i. in footpads 
(A-B) or draining LNs (C-D). (E-F) Three weeks prior to infection, mice were injected 
subcutaneously into the ankle with 50µl of PBS- or clodronate-containing liposomes. ifn-β 
and ifn-α transcript levels were quantified by RT-qPCR in draining LNs 12 hours p.i.. 
Results of one representative of 3 independent experiments were expressed as mean ± SEM 
(n=5) transcript increase relative to a naïve mouse and normalized to housekeeping gene l32. 
Statistical significance was assessed by Student’s t-test, *p<0.05, **p<0.01, ***p<0.001 . 
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Figure S9. Clodronate depletion of macrophages in vivo. 
WT mice were injected subcutaneously in the ankle with 50µl of PBS- or clodronate-
containing liposomes. Three weeks post-treatment, mice were infected in the hind footpads 
with 3 x 106 Lgy stationary-phase promastigotes. LNs cells were recovered 12 hours p.i.. (A) 
FACS plots showed the frequency of macrophages and dendritic cells in LNs. (B-C) Graphs 
showed the percentage of dendritic cells and macrophages in total LNs cells. Results of one 
representative of 3 independent experiments were expressed as mean ± SEM (n=5). Statistical 
significance was assessed by Student's t-test, ***p<0.001. 
